Active Biotech to present at UBS Global Life Sciences Conference


This annual conference is attended by approximately 3,000 investment professionals and pharmaceutical decision-makers.
From Active Biotech will be present; Sven Andréasson CEO and Tomas Leanderson CSO.
The presentation, scheduled to take place on Monday, September 27 at 4:30 P.M. will coverActive Biotech's ongoing clinical development projects within the areas of autoimmunity/inflammation and cancer.
For more details about Active Biotech and ongoing projects, please visit our web page
Contact:Hans Westerberg, Active Biotech US Investor Relations, +1212644 2561
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.

In June, 2004 Active Biotechsigned an agreement with Teva Pharmaceutical Industries to develop and commercialize laquinimod, Active Biotech's novel immunomodulatory compound, which has the potential to be an orally available disease modifying treatment of multiple sclerosis (MS).

Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50